ESMO: In unconventional move, Bayer pits genetically driven cancer drug Vitrakvi against Roche’s Rozlytrek in adjusted comparisonnews2021-09-15T14:30:40+00:00September 15th, 2021|Fierce Pharma|
CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington’s intensifying drug-pricing pushnews2021-09-15T14:13:54+00:00September 15th, 2021|Fierce Pharma|
Amid COVID’s latest surge, Regeneron and Eli Lilly score new antibody supply deals with the U.S.news2021-09-15T13:51:09+00:00September 15th, 2021|Fierce Pharma|
Citing ‘less-than-optimal’ outcomes for Roche’s Evrysdi, Biogen launches high-dose Spinraza trialnews2021-09-15T13:22:31+00:00September 15th, 2021|Fierce Pharma|
Fred Hutch researchers tout Iclusig’s potential to tame cytokine storm in COVID but can’t get Takeda on boardnews2021-09-15T11:54:53+00:00September 15th, 2021|Fierce Pharma|
AbbVie dodges hedge fund lawsuit over failed $55B Shire pursuitnews2021-09-14T19:28:23+00:00September 14th, 2021|Fierce Pharma|
Biohaven’s ambitious Nurtec ODT marketing strategy pays dividends with doctors in migraine market: analystnews2021-09-14T15:33:18+00:00September 14th, 2021|Fierce Pharma|
After regulatory nods, Johnson & Johnson says latest Ebola vaccine data could support prophylactic usenews2021-09-14T13:52:03+00:00September 14th, 2021|Fierce Pharma|
Takeda eyes vaccine business growth amid COVID-19 partnerships and dengue progress, CEO saysnews2021-09-14T13:42:28+00:00September 14th, 2021|Fierce Pharma|
Emergent, after J&J woes, inks $90M deal to help produce Providence Therapeutics’ mRNA COVID-19 vaccinenews2021-09-14T13:42:28+00:00September 14th, 2021|Fierce Pharma|
